Börsch, Natalie
Mücke, Martin
Maier, Andrea
Conrad, Rupert
Pantel, Jean Tori
Sellin, Julia
Mani, Kyros
Chopra, Pradeep
Article History
Accepted: 24 November 2023
First Online: 8 January 2024
Declarations
:
: N. Börsch: Member of the Medical–Scientific Board of <i>Ehlers–Danlos Selbsthilfe</i> e. V. and has received a lecture honorarium from the Ehlers-Danlos Initiative once in the last 5 years. Prof. Dr. Martin Mücke has received lecture and project fees from Kyowa Kirin, TAKEDA, Chiesi, Sanofi and Boehringer Ingelheim Pharma, which are also active in the field of rare diseases, over the past 5 years. A. Maier: Medical–Scientific Board of the <i>Deutsche EDS Initiative and POTS und andere Dysautonomien</i>; research grants: Takeda Pharmaceuticals, Standing Up to POTS Research Fund, Centogene GmbH. Despite these relationships, the authors declare that the data and conclusions presented in this article are objective and independent of these financial relationships. R. Conrad, J.T. Pantel, J. Sellin, K. Mani and P. Chopra declare that they have no competing interests.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.
Free to read: This content has been made available to all.